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Objectives: To test the efficacy of daptomycin, a cyclic lipopeptide antibiotic, against a methicillin-
susceptible Staphylococcus aureus strain in experimental rabbit meningitis and to determine its
penetration into non-inflamed and inflamed meninges
Results: Over a treatment period of 8 h, daptomycin (15 mg/kg) was significantly superior to the com-
parator regimen vancomycin (–4.54 – 1.12 log10/mL for daptomycin versus –3.43 – 1.17 log10/mL for
vancomycin). Daptomycin managed to sterilize 6 out of 10 CSFs compared with 4 out of 10 for
vancomycin. The penetration of daptomycin into inflamedmeninges was5% and2% into non-inflamed
meninges.
Conclusions: The superior bactericidal activity of daptomycin was confirmed in vivo and in time-killing
assays in vitro.
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Introduction
Staphylococcus aureus is the cause of 1–9% of all cases of
bacterial meningitis with mortality rates ranging from 14 to
77%.1–3 Usually, meningitis due to S. aureus occurs in patients
after neurosurgical procedures, head trauma or in those with CSF
shunts (12–19% of the cases). In patients without prior central
nervous system disease, underlying conditions include diabetes
mellitus, alcoholism, haemodialysis, intravenous drug abuse and
malignancies. In an epidemiological study, Schlesinger et al. repor-
ted that 55% of the cases were observed in patients with a variety of
central nervous disorders, i.e. CSF shunts, stroke, trauma, haem-
orrhage, seizure disorders, neoplasm, hydrocephalus and arterio-
venous malformations.3 Other underlying conditions in patients
with community-acquired S. aureus meningitis include sinusitis,
endocarditis, abscess, cellulitis, osteomyelitis and pneumonia.
Mortality in patients with S. aureus meningitis has been reported
to be higher when the way of infection is haematogenous rather
than post-operative (56% versus 18%).2 In patients with CSF
shunts, Staphylococcus epidermidis is the most common cause
of meningitis, accounting for 47–64% of the cases.4
Daptomycin is a new lipopeptide antibiotic with an excellent
bactericidal activity against Gram-positive microorganisms,
including methicillin-susceptible S. aureus (MSSA) and
methicillin-resistant staphylococci.5–7 We have recently shown
that daptomycin was very efficacious in experimental pneumococ-
cal meningitis, sterilizing the CSF of rabbits within 4 h.8 The aim
of this study was to test the efficacy of daptomycin against a
methicillin-susceptible staphylococcal strain in the meningitis
rabbit model.
Material and methods
Staphylococcal strain
The staphylococcal strain MSSA 1112 was kindly provided by
Dr Jose´ Entenza, Department of Infectious Diseases, University
Hospital Lausanne and Professor Philippe Moreillon, Department of
Experimental Microbiology, University of Lausanne, Switzerland.
This strain has been routinely used in experimental endocarditis.9
The strain was grown in Mueller-Hinton broth (MHB) until an approx-
imate density of 108 cfu/mL and was then diluted for both in vitro and
in vivo experiments.
Experimental meningitis model
The experimental rabbit meningitis model described by Dacey and
Sande10 was used in this project. The experimental protocols were
approved by the Kantonales Veterina¨ramt des Kantons Bern.
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Pathogen-free New Zealand rabbits were provided by the Zentral-
tiersta¨lle der Medizinischen Fakulta¨t der Universita¨t Bern, where all
the experiments have been performed.
One day before an experiment, rabbits were anaesthetized by
intramuscular injection of a combination of ketamine and xylazine
to fit prostheses on their calvarium to facilitate subsequent placement
within a stereotactic frame. On the day of the experiment, rabbits
received 1.75 g/kg ethylcarbamate (urethane) subcutaneously and
then 10 mg/kg pentobarbital intravenously to induce deep anaesthesia.
The animals were fixed in stereotactic frames and a 3.5 inch (25G)
spinal needle was introduced into the cisterna magna. Following the
withdrawal of 0.2 mL of CSF, staphylococci (1 · 105 cfu in 0.2 mL
of saline solution) were injected into the subarachnoid space. After
inoculation the animals were brought back to the cages for the night.
About 8 h later, the rabbits were fitted again in the frames using the
techniques and anaesthesia described above. A catheter was fixed in
the femoral artery for serum sampling. A spinal needle was fixed again
in the subarachnoid space. Antibiotics were injected intravenously in
doses described in the literature11,12 (vancomycin 20 mg/kg). Vanco-
mycin doses were standard doses. Daptomycin was injected once
(15 mg/kg) at 0 h.
Vancomycin was given at 0 and 4 h, according to its pharmacokin-
etic properties. CSF (0.2 mL) was sampled at 0, 1, 2, 4, 6 and 8 h after
initiation of therapy. Blood samples were collected at 0.25, 0.5, 1, 2,
3, 4, 5, 6, 7 and 8 h after initiation of therapy. Each group
included untreated controls, daptomycin and vancomycin treated
rabbits, randomly chosen. Experiments were repeated until 10 rabbits
were reached in each group. Killing rates were evaluated by linear
regression analysis, as described previously.13 Results were expressed
as Dlog10 cfu/mL·h and Dlog10 cfu/mL·8 h. For the determination of
the penetration of daptomycin into non-inflamed meninges, blood
and CSFwere sampled just after fixing the rabbits in the frame, without
instillation of bacteria into the CSF space.
In vitro killing assays
The staphylococcal strain MSSA 1112 was grown in MHB supple-
mented with calcium (50 mg/L) to an optical density of 0.3 at 590 nm
and then diluted 40-fold to 106 cfu corresponding approximately to
bacterial concentrations in the CSF of rabbits before initiation of ther-
apy. Daptomycin and vancomycin were added at concentrations cor-
responding to 1·, 5· and 10·MIC. Bacterial titres were determined at
0, 2, 4, 6 and 8 h by serial dilution of samples, plated on agar plates
containing 5% sheep blood and incubated at 37C for 24 h. Experi-
ments were performed in triplicate and results are expressed as mean
log10 cfu/mL – SD.
Determination of antibiotic levels and cfu titres
The concentration of daptomycin in serum and CSFwas determined by
HPLC. This analytical work was kindly performed by Dr Changfu
Chen, Cubist Pharmaceuticals, Lexington. Samples were kept frozen
at –80C and sent on dry ice. The limit of detection was 0.01 mg/L.
The concentration of vancomycin in the CSF was determined by
the agar diffusion method. Standard curves were performed in saline
with 5% rabbit serum in order to mimic CSF protein concentration.14
Bacillus subtilis ATCC 6633 was used as a test strain.15 The intra-day
and inter-day variation of this method was <10% and the limit of
detection of vancomycin was 0.5 mg/L.
Colony forming units were measured by serial dilution of CSF
plated on agar plates with 5% sheep blood and incubated overnight
at 37C.
Statistical analysis
The Student’s t-test and one-way analysis of variance (Newman-Keuls
multiple comparisons test) were used for parametric data. A P value
of <0.05 was considered significant.
Results
The antibacterial efficacy of daptomycin against a methicillin-
susceptible strain is demonstrated in Figure 1. Even when a
concentration around the MIC (1 mg/L) was used, daptomycin
was bactericidal with a decrease in viable cell count of 3.6
log10 after 6 h. At higher concentrations (5 · and 10 · MIC),
daptomycin managed to sterilize the cultures after 6 and 4 h,
respectively. The comparator regimen (vancomycin) was less bac-
tericidal in vitro. 1 · MIC (1 mg/L) of vancomycin produced a
decrease in cfu of 2.3 log10 . 5· and 10· MIC were slightly
superior with antibacterial activities of 3.2 and 3.4 log10, respect-
ively (Figure 2).
One dose of daptomycin (15mg/kg) produced a peak serum level
of 141– 4mg/L decreasing progressively to 75 – 16mg/L at the end
of the experimental period. In the CSF, daptomycin peaked at
4.5mg/L after 2 h, remaining at4mg/L during the entire treatment
period and producedCSF/MIC ratios of4 during the experimental
period (Figure 3, filled squares). The penetration of daptomycin into
inflamed meninges was 5%, determined by comparison of AUC
serum/CSF. In non-infected animals (Figure 3, open squares) dap-
tomycin levels increased slowly and peaked at2.9 mg/L 2 h after
injection and remained approximately stable during the rest of
the experimental period, leading to a penetration of 2% into
non-inflamed meninges. Two injections of vancomycin (20 mg/
kg) produced peak and trough levels between 4.0 and 1.9 and
4.5 and 2.2 mg/L respectively (data not shown).
The killing rates of the different regimens, calculated by linear
regression analysis, are shown in Table 1. Before starting a
therapy, the initial bacterial titre was similar in all treatment
groups. In untreated controls, bacterial titres showed minimal
growth rates, <1 log10 over 8 h (+0.86 – 0.36 log10/mL).
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Figure 1. Daptomycin against MSSA in vitro. Killing rates of daptomycin
(filled squares) in vitro at concentrations corresponding to 1·, 5· and 10·
MIC against a methicillin-susceptible strain. Open squares, untreated controls.
Experiments were performed in triplicate and killing rates are expressed
as means – SD.
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Daptomycin produced a good bactericidal activity against
the methicillin-susceptible staphylococcal strain, leading to a
decrease of 4.54 log10 cfu/mL over 8 h. Daptomycin managed
to sterilize 6 out of 10 CSFs of rabbits. Two doses of vancomycin
sterilized 4 out of 10 CSFs of rabbits and were significantly less
efficacious than daptomycin (–3.43 – 1.17 log10 versus –4.54 –
1.12 log10 for daptomycin; P<0.04).
Discussion
Meningitis due to S. aureus, occurring mostly after head trauma
or neurosurgical interventions, remains one of the most deleteri-
ous infections of the central nervous system. In case of b-lactam
allergy, and when methicillin-resistant strains are suspected,
vancomycin is the treatment of choice. However, the unreliable
penetration for vancomycin into the CSF, especially with addition
of dexamethasone, remains a matter of concern,11,16 underlining
the need of alternative therapies. Daptomycin is a new cyclic
lipopeptide antibiotic with an excellent activity against a variety
of Gram-positive microorganisms, including staphylococci.17,18
We have recently shown that daptomycin was very efficacious
against a penicillin-resistant and a penicillin- and quinolone-
resistant pneumococcal strain in experimental meningitis. The
most interesting feature of that study was the fact that daptomycin
managed to sterilize the CSFs of rabbits within 4 h.8
In this study daptomycin (15 mg/kg) produced serum and CSF
levels comparable to those described previously in pneumococcal
meningitis8 and corresponded to levels obtained in humans with
a dose of 6 mg/kg. We are aware that nafcillin or flucloxacillin is
the standard treatment of MSSA meningitis in humans. However,
because of their pronounced side effect i.e. profuse diarrhoea, we
decided to use vancomycin as the comparator treatment in this
study. The dose of vancomycin (2 · 20 mg/kg) was a standard
dose used in previous studies19,20 and produced CSF levels
similar to those measured in humans with high-dose therapy.21,22
The CSF levels of both treatment groups were roughly equivalent
with analogous CSF/MIC ratios. The superiority of daptomycin is
probably due to its more pronounced bactericidal activity against
staphylococci as demonstrated in time-killing assays in vitro
(Figures 1 and 2). In the same experimental meningitis model,
daptomycin was less efficacious against a staphylococcal strain
than against pneumococci probably owing to the different
MICs (0.06 mg/L for the pneumococcal strains versus 1 mg/L
for the methicillin-susceptible staphylococcal strain). The degree
of inflammation of the meninges also influences the penetration of
daptomycin into the CSF (2% into non-inflamed versus 5%
into inflamed meninges), but to a lesser extent compared with
other antibiotics, e.g. b-lactams, probably owing to its lipophilic
properties.
In summary, the rapid bactericidal activity and the pronounced
efficacy of daptomycin against a methicillin-susceptible staphylo-
coccal strain designate daptomycin as an alternative treatment for
staphylococcal infections of the CNS and confirmed its efficacy
against Gram-positive microorganisms observed in other animal
models.6
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Figure 2. Vancomyin against MSSA in vitro. Killing rates of vancomycin
(filled squares) in vitro at concentrations corresponding to 1·, 5· and 10·
MIC against a methicillin-susceptible strain. Open squares, untreated controls.
Experiments were performed in triplicate and killing rates are expressed as
means – SD.
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Figure 3. CSF levels of daptomycin (1 · 15 mg/kg) in non-inflamed and
inflamed meninges. Daptomycin penetration into the CSF through inflamed
(filled squares) and through non-inflamed meninges (open squares) during
8 h after intravenous injection of 15 mg/kg.
Table 1. Daptomycin monotherapy compared with vancomycin
against a methicillin-susceptible S. aureus (MSSA) in experimental
meningitis
Groups (n)
Inoculum
(log10
cfu/mL)
Killing rates/h
in CSF
(Dlog10 cfu/
mL·h)
Killing rates/
8 h in CSF
(Dlog10 cfu/
mL·8 h)
Controls (10) 5.09 – 0.32 +0.11 – 0.05 +0.86 – 0.36
Daptomycin (10) 5.50 – 0.36 –0.59 – 0.14a –4.54 – 1.12b
Vancomycin (10) 5.18 – 0.32 –0.43 – 0.24a –3.43 – 1.17b
Results are expressed as means – SD.
aDaptomycin versus vancomycin not significant.
bP < 0.04 for daptomycin versus vancomycin.
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